Trovagene Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference

Trovagene, Inc.

, a developer of cell-free molecular diagnostics, announced today that two abstracts (#B175 and #B177) highlighting results from studies of the company's novel, non-invasive cancer mutation monitoring platform will be presented on October 21, 2013 at the AACR-NCI-EORTC[1] International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) Both studies were completed in collaboration with Dr. Filip Janku in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston. Trovagene is developing proprietary cell-free DNA urinary assays for molecular testing as a non-invasive alternative to mutation testing of tumor tissue. The abstracts accepted for presentation during the "Molecular Classification of Tumors" poster session at the AACR-NCI-EORTC conference are: Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by digital droplet PCR (Abstract #B175) Monday, October 21, 12:30 – 3:00 p.m. and 6:30 – 7:30 p.m. Location: Exhibit Hall C-D Non-invasive tumor mutation detection of cell-free urinary DNA using massively parallel deep DNA sequencing (Abstract #B177)